Aptinyx Inc

Aptinyx Inc. is a clinical stage biopharmaceutical company, which engages in discovery, development, and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program. The company was founded by Norbert G. Riedel and Joseph R. Moskal in June 2015 and is headquartered in Evanston, IL.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it intends to offer and sell 12,000,000 shares of its common stock in an underwritten public offering. All of the shares sold in the offering will be sold by Aptinyx. Aptinyx also expects to grant the underwriters a 30-day option to purchase up to an additional 1,800,000 shares t

Aptinyx Announces Proposed Public Offering of Common Stock

APTX stock is soaring on Tuesday after Aptinyx announced very positive results from its trial for a treatment for those with PTSD. The post Aptinyx News: Why APTX Stock Is Skyrocketing Today appeared first on InvestorPlace.

Aptinyx News: Why APTX Stock Is Skyrocketing Today

The biotech's PTSD drug hit the mark in a midstage trial.

Why Aptinyx Stock Is Soaring Today

Aptinyx (APTX) is developing a NMDA receptor-targeted candidate, NYX-783, as potential treatment for post-traumatic stress disorder.

Aptinyx (APTX) Surges on Promising Stress Disorder Study Data

Shares of Aptinyx Inc. shot up 61% on heavy volume in premarket trading Tuesday, putting them on track to open at a 20-month high, after the biopharmaceutical company reported positive results from a Phase 2 trial of its treatment for post-traumatic stress disorder (PTSD). Trading volume was 14.6 million shares, making the stock the most actively traded ahead of the open, and compared with the full-day average of about 269,000 shares.

Aptinyx stock soars on premarket leading volume after positive trial results of PTSD treatment

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced positive results from the first Phase 2 study of its novel NMDA receptor modulator, NYX-783, in 153 patients with post-traumatic stress disorder (PTSD). In the Phase 2 study, NYX-783 demonstrated statistically significant and clinically meaningful efficacy results and a favorable adve

Aptinyx Reports Positive, Statistically Significant, Top-line Data From Phase 2 Study of NYX-783 in Patients With Post-Traumatic Stress Disorder

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has re-activated study sites and recommenced patient recruitment in a Phase 2 study of NYX-2925 in patients with fibromyalgia. Enrollment in the study had been suspended in March 2020 due to the escalation of the COVID-19 pandemic in the United States. “We are very pleased to

Aptinyx Recommences Patient Recruitment in Phase 2 Study of NYX-2925 in Patients with Fibromyalgia

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc.

Aptinyx to Present at Upcoming Virtual Investor Conferences

CymaBay Therapeutics

Evolus

iBio

Sientra

While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 Red-Hot Biotech and Medtech Stocks Under $10 With Massive Upside Potential

Aptinyx Inc (APTX) CEO Norbert Riedel on Q2 2020 Results - Earnings Call Transcript

Aptinyx Inc. (APTX) delivered earnings and revenue surprises of 6.90% and -41.94%, respectively, for the quarter ended June 2020.

Aptinyx Inc. (APTX) Reports Q2 Loss, Misses Revenue Estimates

Aptinyx Reports Second Quarter 2020 Financial Results and Highlights

Aptinyx to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

Aptinyx to Report Second Quarter Financial Results on Thursday, August 13, 2020

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it will host a virtual R&D Day focused on the company’s development efforts in post-traumatic stress disorder (PTSD) on Wednesday, August 5, 2020, from 10:00 a.m. to 11:30 a.m. ET. The meeting will feature a presentation from Murray B. Stein MD, MPH, FRCPC. Dr. Stein is Disti

Aptinyx to Host PTSD-Focused R&D Day on August 5th, 2020

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, will be added as a member of the US small-cap Russell 2000® Index. The addition will be effective after the US market opens on June 29, 2020 as part of the 2020 Russell US Indexes annual reconstitution. Inclusion in the Russell 2000® Index, which remains in place for one year, is based on membership

Aptinyx to be Added to Russell 2000® Index

Aptinyx PTSD Trial And Other News: The Good, Bad And Ugly Of Biopharma

Data readout expected by late 2020 Data readout expected by late 2020

Aptinyx Completes Enrollment in Phase 2 Exploratory Study of NYX-783 in Post-Traumatic Stress Disorder

Is  (APTX) Outperforming Other Medical Stocks This Year?

Is Aptinyx (APTX) Stock Outpacing Its Medical Peers This Year?

Aptinyx Inc. (APTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

Aptinyx Inc. (APTX) Moves to Strong Buy: Rationale Behind the Upgrade

As of late, it has definitely been a great time to be an investor in Aptinyx.

Aptinyx's Shares March Higher, Can It Continue?

Aptinyx Inc. (APTX) CEO Norbert Riedel on Q1 2020 Results - Earnings Call Transcript

Aptinyx Inc. (APTX) delivered earnings and revenue surprises of -3.03% and -9.61%, respectively, for the quarter ended March 2020.

Aptinyx Inc. (APTX) Reports Q1 Loss, Lags Revenue Estimates

Over 90% of target enrollment achieved to date in Phase 2 exploratory study of NYX-783 in PTSD; data readout expected in late 2020

Aptinyx Reports First Quarter 2020 Financial Results and Highlights

Aptinyx Inc (APTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Aptinyx Inc Stock (APTX)